Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Cancer
|
April 23, 2014
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study
Emilio Bajetta, Laura Catena, Nicola Fazio, et al.
Anticancer Research
|
June 9, 2016
Once Daily Accelerated Partial Breast Irradiation: Preliminary Results with Helical Tomotherapy®
Ugo DE Paula, Rolando M D'Angelillo, Raffaele Barbara, et al.
Journal of Cancer Research and Clinical Oncology
|
April 23, 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Clara Natoli, Patrizia Vici, Isabella Sperduti, et al.
Breast Cancer Research and Treatment
|
April 12, 2011
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
Manuela Campiglio, Rosaria Bufalino, Marco Sandri, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 25, 2020
Long-Term Outcomes of Once-Daily Accelerated Partial-Breast Irradiation With Tomotherapy: Results of a Phase 2 Trial
Ugo de Paula, Rolando Maria D'Angelillo, Angela Damiana Andrulli, et al.
International Journal of Medical Sciences
|
April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
Eriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
International Journal of Cancer
|
July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
Laura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Cancer
|
April 23, 2014
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study
Emilio Bajetta, Laura Catena, Nicola Fazio, et al.
Anticancer Research
|
June 9, 2016
Once Daily Accelerated Partial Breast Irradiation: Preliminary Results with Helical Tomotherapy®
Ugo DE Paula, Rolando M D'Angelillo, Raffaele Barbara, et al.
Journal of Cancer Research and Clinical Oncology
|
April 23, 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Clara Natoli, Patrizia Vici, Isabella Sperduti, et al.
Breast Cancer Research and Treatment
|
April 12, 2011
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
Manuela Campiglio, Rosaria Bufalino, Marco Sandri, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 25, 2020
Long-Term Outcomes of Once-Daily Accelerated Partial-Breast Irradiation With Tomotherapy: Results of a Phase 2 Trial
Ugo de Paula, Rolando Maria D'Angelillo, Angela Damiana Andrulli, et al.
International Journal of Medical Sciences
|
April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
Eriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
International Journal of Cancer
|
July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
Laura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Page
of 2